ENTITY
3SBio

3SBio (1530 HK)

196
Analysis
Health Care • China
3SBio is a leading biotechnology company engaged in the research, development, manufacturing, and marketing of biopharmaceutical products. The company's diverse portfolio addresses therapeutic areas such as nephrology, oncology, supportive cancer care, inflammation, infectious diseases, autoimmune diseases, metabolism, and dermatology, with key products including EPIAO and TPIAO. 3SBio was founded in 1993 and is headquartered in Shenyang, China.
more
•05 Feb 2015 16:01

Introducing Long Term Leaders - Focussed Insights for your Core Holdings

We are pleased to announce the roll out of our latest content vertical: Long Term Leaders. Under this category,  we have identified companies that...

Logo
497 Views
Share
•05 Mar 2026 08:55

Pre-IPO Alebund Pharmaceuticals (Jiangsu) Limited - The Pipeline and the Outlook

​Alebund's focus on kidney disease helps build competitive barriers, but competitive advantage is hindered by fierce competition and VBP in China,...

Logo
230 Views
Share
bullish•MiniMax
•04 Mar 2026 20:59

MiniMax-WP: Path Way to HSI Inclusion

A US$33bn AI company sitting outside the HSI, but perhaps not for long. We examine the pathway, the precedents, and the timeline ahead.

Logo
555 Views
Share
bearish•Mirxes
•23 Feb 2026 09:44

Aequitas: Mirxes IPO Lockup - 44% of the Stock up for Lockup Release, with a Lot of CCASS Movement

Mirxes Holding (2629 HK) raised around US$130m in its Hong Kong listing in May 2025. The lockup on its pre-IPO shareholders is set to expire soon.

Logo
305 Views
Share
bearish•Quantitative Analysis
•15 Feb 2026 10:10

HK Short Interest Weekly: Zto Express, HSBC, Hua Hong Semiconductor, Techtronic

We analyzed the latest HK SFC report for aggregate short position as of Feb 6th and highlight short interest changes in Zto Express, HSBC, Hua Hong...

Logo
334 Views
Share
x